Please Wait...

BioClinica Partners with Mirada Medical for New Era of Molecular Image Analysis

– Announces Record Backlog of $125.8 million –

March 30, 2012

– Mirada XD3 Analysis Software to Integrate with BioREAD Imaging Core Lab System for PET and Molecular Imaging in Oncology and Other Therapeutic Areas –

March 30, 2012.  NEWTOWN, PA – BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced a partnership with Mirada Medical, a leading provider of medical image analysis software. BioClinica will integrate Mirada's XD3 software solution into its imaging core lab technology to further enhance its PET capabilities and expertise for molecular imaging trials.

Mirada Medical's software provides unique tools and efficient workflows for the quantification and tracking of findings for major modalities including PET, CT, MR and MR/PET. After a careful evaluation of available molecular imaging solutions, BioClinica selected Mirada for its advanced image analysis capabilities and ability to handle not only PET images but CT and MRI as well. This will further enhance BioClinica's image registration and fusion capabilities in studies where multiple modalities are utilized.

BioClinica's strategy goes beyond a standard utilization of Mirada's software by creating a strategic partnership that will foster innovation as the molecular imaging field continues to develop. BioClinica will integrate Mirada's XD3 image analysis software platform into its processes and workflows, adopting an innovative design that will advance the clinical capabilities of BioClinica technologies such as BioPACS and BioREAD. These high-performing imaging workflow and processing programs will now have expanded capabilities to help trial sponsors harness the superior imaging results that are achievable through PET scans and multi-modal technology.

Through this partnership, BioClinica's PET image processing capabilities will extend oncology clinical trials with support for the following features:

  • Enhanced capabilities for PERCIST tumor response assessment criteria
  • Normalization of uptake by body weight, lean body mass, or body surface area for SUV measurements
  • Registration and fusion capabilities between PET, CT, and MR
  • Customizable workflow and user interface to provide flexibility in the independent read design

"Adding Mirada technology to our oncology trial process takes BioClinica's already robust imaging core lab services to a new level," said Dr. Andy Dzik-Jurasz, BioClinica's Senior Medical Director of Medical Affairs. "By adding XD3 to our workflow, BioClinica will offer the most sophisticated level of clinical analysis available for oncology PET scan image processing."

"Mirada is delighted to partner with an innovative industry leader like BioClinica," said Timor Kadir, Chief Science and Technology Officer at Mirada Medical. "We are excited to see BioClinica's innovative utilization of XD3's superior quantification and world class image fusion to achieve more accurate and reproducible results for their trial sponsors."

As part of this partnership, Mirada Medical will present at BioClinica's upcoming User Conference in October. The BioClinica User Conference consists of two days of valuable presentations, case studies and discussions designed to help BioClinica imaging core lab customers and eClinical solution users discover new ways to run faster, more efficient clinical trials. To learn more about the conference, visit

About Mirada Medical Ltd
Mirada Medical is a leading international brand in medical imaging. The company develops advanced software applications which help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada's products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumor board and elsewhere.

Mirada specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.

Mirada's advanced software products are available throughout the world under its own brand, and on an OEM basis through a select number of the world's leading healthcare companies.

Mirada Medical was originally spun out of the University of Oxford. The company's technologies and products continue to be developed by their team of specialists, engineers and world-renowned scientists at Mirada's world headquarters in Oxford, England.

Mirada Medical, Mirada XD3, Caseaccess and Casemeeting are all trademarks of Mirada Medical Ltd.

For more information, visit

About Bioclinica
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging & Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth Solutions segment comprises the eClinical Solutions platform; Randomization & Trial Supply Management; Financial Lifecycle Solutions; Safety & Regulatory Solutions; Strategic Consulting Services; App xChange Alliances; and eHealth Cloud Services. Under the Global Clinical Research segment, Bioclinica offers a network of investigative sites, patient recruitment services, and a post-approval research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices and research sites in the U.S., Europe, Asia, and Latin America.


Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @bioclinica: Attending CBI's IRT conf? Catch 10/27 @bioclinica GSK talk on bens of sponsor controlled #IRT. Here's the core tech https:…
bioclinica (3 days ago)
RT @Xtalks: Clinical Event Adjudication: Comprehensive and Efficient Dossier Review Using a Global On-Line Solution @bioclinica https://t.c…
bioclinica (3 days ago)
RT @eClinical_Jen: Good Morning from NJ! @bioclinica is a sponsor of the clinical supply show because we have awesome supply forcasting and…
bioclinica (4 days ago)
Attending CBI's IRT conf? Catch 10/27 @bioclinica GSK talk on bens of sponsor controlled #IRT. Here's the core tech…
bioclinica (5 days ago)
RT @Xtalks: #Cardiovascular Imaging for Monitoring Safety: Visualizing Outcomes @bioclinica
bioclinica (5 days ago)
Want stellar imaging acquisition & assessment in your #clinicaltrial ? Get tips in @bioclinica 's Tim Crowe's blog
bioclinica (6 days ago)

Latest Blogs: